Ally Bridge Group NY LLC Sells 364,728 Shares of Definium Therapeutics, Inc. $DFTX

Ally Bridge Group NY LLC trimmed its holdings in shares of Definium Therapeutics, Inc. (NASDAQ:DFTX) by 50.2% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 361,444 shares of the company’s stock after selling 364,728 shares during the period. Definium Therapeutics makes up approximately 2.6% of Ally Bridge Group NY LLC’s holdings, making the stock its 14th largest position. Ally Bridge Group NY LLC owned approximately 0.37% of Definium Therapeutics worth $4,261,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the stock. Schonfeld Strategic Advisors LLC purchased a new stake in shares of Definium Therapeutics in the 3rd quarter worth approximately $419,000. Virtu Financial LLC purchased a new position in Definium Therapeutics during the third quarter valued at $379,000. Orbimed Advisors LLC bought a new stake in Definium Therapeutics in the third quarter worth $4,337,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Definium Therapeutics by 178.3% in the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 117,239 shares of the company’s stock worth $1,382,000 after acquiring an additional 75,110 shares in the last quarter. Finally, Two Sigma Investments LP grew its stake in shares of Definium Therapeutics by 424.9% in the third quarter. Two Sigma Investments LP now owns 296,443 shares of the company’s stock worth $3,495,000 after acquiring an additional 239,965 shares during the last quarter. 27.91% of the stock is owned by institutional investors.

Definium Therapeutics Trading Up 0.4%

Shares of NASDAQ:DFTX opened at $18.06 on Friday. The company has a debt-to-equity ratio of 0.12, a current ratio of 6.29 and a quick ratio of 6.29. Definium Therapeutics, Inc. has a 1 year low of $4.70 and a 1 year high of $19.62. The company has a market cap of $1.78 billion, a P/E ratio of -8.48 and a beta of 2.56. The stock’s fifty day moving average price is $16.58 and its 200-day moving average price is $13.40.

Insider Activity

In other news, insider Daniel Karlin sold 5,600 shares of Definium Therapeutics stock in a transaction that occurred on Friday, December 26th. The shares were sold at an average price of $13.15, for a total value of $73,640.00. Following the completion of the sale, the insider directly owned 425,025 shares in the company, valued at $5,589,078.75. The trade was a 1.30% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Robert Barrow sold 25,791 shares of the stock in a transaction that occurred on Friday, December 26th. The shares were sold at an average price of $13.15, for a total transaction of $339,151.65. Following the transaction, the chief executive officer owned 778,477 shares in the company, valued at approximately $10,236,972.55. This trade represents a 3.21% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 42,667 shares of company stock valued at $561,071 in the last 90 days. 2.26% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on DFTX. JonesTrading initiated coverage on Definium Therapeutics in a report on Tuesday, December 23rd. They set a “buy” rating and a $61.00 price target for the company. Chardan Capital upgraded shares of Definium Therapeutics to a “strong-buy” rating in a research note on Wednesday, November 19th. Robert W. Baird set a $37.00 price objective on shares of Definium Therapeutics in a research report on Thursday, January 29th. Royal Bank Of Canada lifted their target price on shares of Definium Therapeutics from $20.00 to $36.00 and gave the stock an “outperform” rating in a report on Friday, January 23rd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Definium Therapeutics in a research note on Thursday, January 22nd. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $35.70.

Definium Therapeutics Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.